BioPharma Credit PLC
BOPCF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $77,152 | $45,312 | $79,145 | $57,221 |
| % Growth | 70.3% | -42.7% | 38.3% | – |
| Cost of Goods Sold | $10,006 | -$12,240 | $12,240 | $18,629 |
| Gross Profit | $83,779 | $57,552 | $79,145 | $57,221 |
| % Margin | 108.6% | 127% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $11,145 | -$5,249 | $7,218 | $19,693 |
| SG&A Expenses | $11,145 | -$5,069 | $7,218 | $19,693 |
| Sales & Mktg Exp. | $0 | $180 | $0 | $0 |
| Other Operating Expenses | $0 | $130 | $0 | $0 |
| Operating Expenses | $11,145 | -$4,939 | $7,218 | $19,693 |
| Operating Income | $72,634 | $50,251 | $71,927 | $37,528 |
| % Margin | 94.1% | 110.9% | 90.9% | 65.6% |
| Other Income/Exp. Net | $149 | $89 | -$89 | -$5 |
| Pre-Tax Income | $72,783 | $50,340 | $71,838 | $37,523 |
| Tax Expense | $0 | $0 | $0 | -$7 |
| Net Income | $72,783 | $50,340 | $71,838 | $37,523 |
| % Margin | 94.3% | 111.1% | 90.8% | 65.6% |
| EPS | 0.063 | 0.042 | 0.058 | 0.029 |
| % Growth | 50.7% | -27.2% | 100.3% | – |
| EPS Diluted | 0.063 | 0.042 | 0.058 | 0.029 |
| Weighted Avg Shares Out | 1,150,156 | 1,222,360 | 1,246,077 | 1,302,701 |
| Weighted Avg Shares Out Dil | 1,150,151 | 1,222,360 | 1,246,077 | 1,302,669 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,490 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$72,758 | $71,838 | -$71,838 | -$37,530 |
| EBITDA | $0 | -$71,838 | $71,838 | -$7 |
| % Margin | 0% | -158.5% | 90.8% | -0% |